{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T03:48:00Z","timestamp":1782877680923,"version":"3.54.5"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T00:00:00Z","timestamp":1711238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,3]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Despite advancing treatment methods, esophageal cancer (EC) maintains a high mortality rate and poor prognosis. Through various mechanisms, aspirin has been suggested to have a chemopreventive effect on EC. However, the long-term impact, particularly regarding the rate of metastasis, needs to be further elucidated. NIS 2016\u20132020 was used to identify adult patients (age\u2009&amp;gt;\u200918\u00a0years) with EC using ICD-10 codes. Patients with missing demographics and mortality were excluded. Patients were stratified into two groups based on aspirin use. Data were collected on patient demographics, Elixhauser Comorbidity Index (ECI), and comorbidities (hypertension, chronic pulmonary disease, coronary artery disease (CAD), chronic kidney disease (CKD), congestive heart failure (CHF), coagulopathy, alcohol use, smoking, and obesity). The outcomes studied were rates of total metastasis, gastrointestinal (GI) metastasis, non-GI metastasis, and lymphoid metastasis. Multivariate logistic regression analysis was performed to evaluate the impact of aspirin use on various metastases after adjusting for patient demographics, comorbidities, and ECI. Out of 190,655 patients, 20,650 (10.8%) patients were aspirin users. Majority of the patients in the aspirin group were aged\u2009&amp;gt;\u200965\u00a0years (74.7%), males (82.1%), White race (84%), and had medicare insurance (71%). There was a higher incidence of diabetes, hypertension, chronic pulmonary disease, CAD, CKD, CHF, and smoking in aspirin users than non-aspirin users. Patients with aspirin users had a lower incidence of metastasis (28.9% vs. 38.7%, P\u2009&amp;lt;\u20090.001), GI metastasis (14.2% vs. 20.6%, P\u2009&amp;lt;\u20090.001), non-GI metastasis (15.1% vs. 22%, P\u2009&amp;lt;\u20090.001), and lymphoid metastasis (8.9% vs. 11.3%, P\u2009&amp;lt;\u20090.001) than non-aspirin users. After adjusting for confounding factors, patients with aspirin use had lower odds of having metastasis (aOR-0.73, 95% CI-0.70-0.77, P\u2009&amp;lt;\u20090.001). Our study noted that aspirin use is associated with a reduction in the rate of metastasis in patients with EC. These studies support the use of aspirin in patients with EC and suggest the need for further studies to understand the mechanism by which aspirin use reduces metastasis in patients with EC.<\/jats:p>","DOI":"10.1093\/dote\/doae022","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T11:35:41Z","timestamp":1711366541000},"source":"Crossref","is-referenced-by-count":3,"title":["Impact of aspirin use on rates of metastasis in patients with esophageal cancer: insights from the National Inpatient Sample"],"prefix":"10.1093","volume":"37","author":[{"given":"Jay","family":"Patel","sequence":"first","affiliation":[{"name":"Department of Gastroenterology , Hepatology, and Nutrition, , Cleveland, OH , USA"},{"name":"Cleveland Clinic , Hepatology, and Nutrition, , Cleveland, OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejasvini","family":"Khanna","sequence":"additional","affiliation":[{"name":"Department of Medicine, Maulana Azad Medical College , New Delhi , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8365-7240","authenticated-orcid":false,"given":"Aalam","family":"Sohal","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Liver Institute Northwest , Seattle, WA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armaan","family":"Dhaliwal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Arizona , Tucson, AZ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunza","family":"Chaudhry","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of California, San Francisco , Fresno, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivam","family":"Kalra","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dayanand Medical College and Hospital , Ludhiana , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishandeep","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dayanand Medical College and Hospital , Ludhiana , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dino","family":"Dukovic","sequence":"additional","affiliation":[{"name":"Ross University School of Medicine , Miramar, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanwal","family":"Bains","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Arizona , Tucson, AZ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,24]]},"reference":[{"issue":"3","key":"2024070311404083700_ref1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.14423\/SMJ.0000000000001226","article-title":"Esophageal cancer: an updated review","volume":"114","author":"DiSiena","year":"2021","journal-title":"South Med J"},{"issue":"2","key":"2024070311404083700_ref2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.21037\/acs.2017.03.03","article-title":"Overview of esophageal cancer","volume":"6","author":"Abbas","year":"2017","journal-title":"Ann Cardiothorac Surg"},{"issue":"3","key":"2024070311404083700_ref3","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.asjsur.2016.10.005","article-title":"Esophageal cancer: risk factors, genetic association, and treatment","volume":"41","author":"Huang","year":"2018","journal-title":"Asian J Surg"},{"issue":"26","key":"2024070311404083700_ref4","doi-asserted-by":"crossref","first-page":"7933","DOI":"10.3748\/wjg.v21.i26.7933","article-title":"Esophageal cancer: risk factors, screening and endoscopic treatment in Western and Eastern countries","volume":"21","author":"Domper Arnal","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"1","key":"2024070311404083700_ref5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12943-020-01294-3","article-title":"Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy","volume":"20","author":"Bhat","year":"2021","journal-title":"Mol Cancer"},{"issue":"7","key":"2024070311404083700_ref6","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1038\/bjc.2013.411","article-title":"Low-dose aspirin use and cancer characteristics: a population-based cohort study","volume":"109","author":"Jonsson","year":"2013","journal-title":"Br J Cancer"},{"issue":"6","key":"2024070311404083700_ref7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.clon.2013.03.001","article-title":"Aspirin as a treatment for cancer","volume":"25","author":"Phillips","year":"2013","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"5","key":"2024070311404083700_ref8","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(12)70112-2","article-title":"Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials","volume":"13","author":"Algra","year":"2012","journal-title":"Lancet Oncol"},{"issue":"10","key":"2024070311404083700_ref9","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa021633","article-title":"A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer","volume":"348","author":"Sandler","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"2024070311404083700_ref10","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/ijc.24757","article-title":"Cyclooxygenase-2 inhibition inhibits PI3K\/AKT kinase activity in epithelial ovarian cancer","volume":"126","author":"Uddin","year":"2010","journal-title":"Int J Cancer"},{"issue":"3","key":"2024070311404083700_ref11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.14740\/wjon1601","article-title":"Impact of aspirin use on outcomes in patients with hepatocellular cancer: a nationwide analysis","volume":"14","author":"Dhaliwal","year":"2023","journal-title":"World J Oncol"},{"issue":"2","key":"2024070311404083700_ref12","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/pubmed\/fdz114","article-title":"Low-dose aspirin use and cancer-specific mortality: a meta-analysis of cohort studies","volume":"43","author":"Wang","year":"2021","journal-title":"J Public Health (Oxf)"},{"issue":"12","key":"2024070311404083700_ref13","first-page":"831","article-title":"Aspirin chemoprevention in Barrett esophagus: is the risk worth the benefit?","volume":"8","author":"Jankowski","year":"2012","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"4","key":"2024070311404083700_ref14","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.21037\/jtd.2018.03.110","article-title":"Aspirin acts in esophageal cancer: a brief review","volume":"10","author":"Hao","year":"2018","journal-title":"J Thorac Dis"},{"key":"2024070311404083700_ref15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3389\/fendo.2020.00003","article-title":"Aspirin and its potential preventive role in cancer: an umbrella review","volume":"11","author":"Song","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"2024070311404083700_ref16","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.annonc.2020.02.012","article-title":"Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019","volume":"31","author":"Bosetti","year":"2020","journal-title":"Ann Oncol"},{"key":"2024070311404083700_ref17","first-page":"297","article-title":"Clinical evidence for the use of aspirin in the treatment of cancer","volume":"7","author":"Langley","year":"2013","journal-title":"Ecancermedicalscience"},{"issue":"4","key":"2024070311404083700_ref18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152402","article-title":"Aspirin in the treatment of cancer: reductions in metastatic spread and in mortality: a systematic review and meta-analyses of published studies","volume":"11","author":"Elwood","year":"2016","journal-title":"PloS One"},{"issue":"6","key":"2024070311404083700_ref19","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.amjmed.2012.01.017","article-title":"Low-dose aspirin and cancer mortality: a meta-analysis of randomized trials","volume":"125","author":"Mills","year":"2012","journal-title":"Am J Med"},{"issue":"2","key":"2024070311404083700_ref20","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s10620-014-3349-2","article-title":"Aspirin and nonsteroidal anti-inflammatory drug use and the risk of Barrett's esophagus","volume":"60","author":"Schneider","year":"2015","journal-title":"Dig Dis Sci"},{"issue":"8","key":"2024070311404083700_ref21","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/bjc.2011.289","article-title":"Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?","volume":"105","author":"Langley","year":"2011","journal-title":"Br J Cancer"},{"key":"2024070311404083700_ref22","author":"HCUP National Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP)","year":"2012"},{"key":"2024070311404083700_ref23","author":"Elixhauser Comorbidity Software Refined for ICD-10-CM Healthcare Cost and Utilization Project (HCUP)","year":"2021"},{"issue":"2","key":"2024070311404083700_ref24","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.critrevonc.2014.01.010","article-title":"Targeted therapies in metastatic esophageal cancer: advances over the past decade","volume":"91","author":"Mohamed","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"2024070311404083700_ref25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/gast.2003.50008","article-title":"Protective association of aspirin\/NSAIDs and esophageal cancer: a systematic review and meta-analysis","volume":"124","author":"Corley","year":"2003","journal-title":"Gastroenterology"},{"issue":"9759","key":"2024070311404083700_ref26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","article-title":"Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomized trials","volume":"377","author":"Rothwell","year":"2011","journal-title":"Lancet"},{"issue":"9","key":"2024070311404083700_ref27","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/bjc.2016.65","article-title":"The effect of aspirin and nonsteroidal anti-inflammatory drug use after diagnosis on survival of oesophageal cancer patients","volume":"114","author":"Staalduinen","year":"2016","journal-title":"Br J Cancer"},{"issue":"5","key":"2024070311404083700_ref28","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1245\/s10434-009-0382-z","article-title":"A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia","volume":"16","author":"Liu","year":"2009","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"2024070311404083700_ref29","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/1756283X16657985","article-title":"Prediagnosis aspirin use and outcomes in a prospective cohort of esophageal cancer patients","volume":"9","author":"Araujo","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"issue":"4","key":"2024070311404083700_ref30","doi-asserted-by":"crossref","DOI":"10.1177\/03000605221089799","article-title":"Effect of taking aspirin before diagnosis on the prognosis of esophageal squamous cell carcinoma and analysis of prognostic factors","volume":"50","author":"Jiang","year":"2022","journal-title":"J Int Med Res"},{"issue":"1","key":"2024070311404083700_ref31","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1186\/s12885-020-07117-4","article-title":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","volume":"20","author":"Lin","year":"2020","journal-title":"BMC Cancer"},{"issue":"11","key":"2024070311404083700_ref32","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S2468-1253(19)30289-4","article-title":"Aspirin as an adjuvant treatment for cancer: feasibility results from the add-aspirin randomised trial","volume":"4","author":"Joharatnam-Hogan","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"2024070311404083700_ref33","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.biopha.2013.11.006","article-title":"Aspirin reduces lung cancer metastasis to regional lymph nodes","volume":"68","author":"Ogawa","year":"2014","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"2024070311404083700_ref34","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1590\/S0102-86502012001100009","article-title":"Effects of aspirin on mesenteric lymph nodes of rabbits as basis for its use on lymph nodes metastases","volume":"27","author":"Batista","year":"2012","journal-title":"Acta Cir Bras"},{"issue":"15","key":"2024070311404083700_ref35","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1158\/0008-5472.CAN-13-2679","article-title":"Recent prediagnostic aspirin use, lymph node involvement, and 5-year mortality in women with stage I-III breast cancer: a nationwide population-based cohort study","volume":"74","author":"Barron","year":"2014","journal-title":"Cancer Res"},{"issue":"3","key":"2024070311404083700_ref36","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/1358863X18760718","article-title":"Aspirin suppresses components of lymphangiogenesis and lymphatic vessel remodeling by inhibiting the NF-\u03baB\/VCAM-1 pathway in human lymphatic endothelial cells","volume":"23","author":"Prangsaengtong","year":"2018","journal-title":"Vasc Med"},{"issue":"4","key":"2024070311404083700_ref37","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1213\/ANE.0000000000005346","article-title":"Overview and limitations of database research in anesthesiology: a narrative review","volume":"132","author":"Abdel-Kader","year":"2021","journal-title":"Anesth Analg"}],"container-title":["Diseases of the Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/37\/7\/doae022\/58403284\/doae022.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/37\/7\/doae022\/58403284\/doae022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T11:46:11Z","timestamp":1720007171000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/dote\/article\/doi\/10.1093\/dote\/doae022\/7634430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,24]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,3,24]]},"published-print":{"date-parts":[[2024,7,3]]}},"URL":"https:\/\/doi.org\/10.1093\/dote\/doae022","relation":{},"ISSN":["1120-8694","1442-2050"],"issn-type":[{"value":"1120-8694","type":"print"},{"value":"1442-2050","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,3,24]]},"article-number":"doae022"}}